Overview

Bioavailability Study Of PF-00868554 Administered As 3x250mg Oral Tablets (Wet Granulate, 3x250mg Oral Tablets (Dry Granulate) And 750mg Solution Under Fed State

Status:
Completed

Trial end date:
2009-06-01

Target enrollment:

Participant gender:

Summary

This study will test two different formulations. The results will be used to select formulation for phase 3.

Phase:

Phase 1

Details

Lead Sponsor:

Pfizer